In obese hypertensives cholecalciferol inhibits circulating TH17 cells but not macrophage infiltration on adipose tissue.
Adipose tissue
Cholecalciferol
Hypertension
Macrophages
Th17
Treg-regulatory
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
03
10
2022
revised:
13
01
2023
accepted:
17
01
2023
pubmed:
28
1
2023
medline:
15
2
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
In arterial hypertension, increased Th17 cells and reduced Tregs are the hallmarks of immunological dysfunction and the basis for the investigation of immunomodulatory drugs. Although cholecalciferol is not a primary immunomodulator, it has recognized action on immune cells, leading us to hypothesise if cholecalciferol can induce a more tolerogenic phenotype in obese hypertensives. In a phase-2, single-centre, randomised, open, 24-week trial, we assigned adults with obesity-associated hypertension and vitamin D deficiency to receive usual therapy plus 50,000 IU/week of cholecalciferol or usual therapy alone. The primary endpoint was the percentual variation in T CD4
Identifiants
pubmed: 36706826
pii: S1521-6616(23)00023-2
doi: 10.1016/j.clim.2023.109244
pii:
doi:
Substances chimiques
Cholecalciferol
1C6V77QF41
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109244Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.